July 6, 2017 / 8:22 PM / 18 days ago

BRIEF-Conatus announces effectiveness of exclusive license with Novartis

1 Min Read

July 6 (Reuters) - Conatus Pharmaceuticals Inc-

* Conatus Pharmaceuticals - exclusive license with Novartis for global development and commercialization of emricasan has become effective under terms

* Conatus Pharmaceuticals - projecting a balance of cash, cash equivalents and marketable securities of between $55 million and $65 million at year-end 2017

* Conatus Pharmaceuticals Inc - license became effective on July 5, 2017, upon conatus' receipt of a $7 million payment

* Conatus Pharmaceuticals - believes current financial resources sufficient to maintain operations & ongoing clinical development activities through 2019 end Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below